Nova Eye Medical Limited (ASX:EYE) has disclosed the issue of 21,000 unquoted performance rights to key management personnel, with the securities issued on 19 November 2026 under the company's employee incentive scheme.

Key Points

  • 21,000 performance rights (ASX security code: EYEAC) were issued on 19 November 2026
  • The securities were issued to key management personnel or an associate
  • The performance rights are unquoted and not intended to be quoted on ASX
  • Following the issue, total EYEAC performance rights on issue stand at 70,000
  • The issue was made under Listing Rule 7.2 Exception 13 and did not require security holder approval

Performance Rights Issue Details

Nova Eye Medical Limited issued 21,000 performance rights under the ASX security code EYEAC on 19 November 2026. The filing confirms the securities were issued to key management personnel or an associate of key management personnel. The performance rights form part of an existing class of unquoted securities and are not intended to be quoted on the ASX. The issue was made as a new announcement, with the company disclosing that the securities do not rank equally in all respects from their issue date with the existing issued securities in that class.

Employee Incentive Scheme and Listing Rule Compliance

According to the filing, the performance rights were issued under the company's employee incentive scheme. The issue was made pursuant to Listing Rule 7.2 Exception 13, meaning security holder approval under Listing Rule 7.1 was not required. The company referenced a document lodged with ASX detailing the terms of the employee incentive scheme. Nova Eye Medical Limited is registered with ABN 15007702927 and trades on the ASX under the issuer code EYE.

Securities on Issue Following the Grant

Following the issue of the 21,000 performance rights, the total number of EYEAC performance rights on issue stands at 70,000, as disclosed in the filing's securities on issue table. The company's quoted ordinary fully paid shares (ASX code: EYE) remain at 284,921,093. The filing notes that the figures for securities on issue are automatically generated and may not reflect the entity's current issued capital if other forms are currently with ASX for processing at the time of the disclosure.